Sun Pharma to acquire shares of Israeli firm Tarsius Pharma for Rs 21 crore
Tarsius is an early stage research and development company focusing on the development of drug candidates in the field of ophthalmology, it added.
New Delhi: Drug major Sun Pharmaceutical Industries said it has agreed to acquire 18.75 per cent shares of Israel-based Tarsius Pharma for a cash consideration of USD 3 million (over Rs 21 crore). One of the company's wholly-owned subsidiaries has agreed to acquire 3,45,622 ordinary shares of Tarsius Pharma, of a nominal value of NIS 0.01 each by way of subscription, representing 18.75 per cent of shares of Tarsius on a fully diluted basis, Sun Pharma said in a filing to BSE.
"Cost of acquisition is USD 3 million," it added.
An indicative time period for completion of the acquisition is before September 15, 2018, Sun Pharma said.
Tarsius is an early stage research and development company focusing on the development of drug candidates in the field of ophthalmology, it added.
Shares of Sun Pharmaceutical Industries closed at Rs 639.50 per scrip on BSE, down 3.72 per cent from its previous close.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd